Articles tagged with 'study' | BIOTRONIK

BIOTRONIK - Archive (study)

2020
13
May
2020
| 13:30 Europe/Amsterdam
Results just published in Circulation Arrhythmia and Electrophysiology confirm that BIOTRONIK Home Monitoring® provides safe and cost-effective remote management of pacemaker patients,1 indicating that it can safely replace the common practice of rou...
Read more
06
May
2020
| 09:24 Europe/Amsterdam
According to recently presented TICO trial data, patients with acute coronary syndrome (ACS) treated with BIOTRONIK’s Orsiro® drug eluting stent (DES) benefit from stopping aspirin three months after stenting and continuing only with ticagrelor monot...
Read more
24
February
2020
| 00:00 Europe/Amsterdam
BIOTRONIK today announced three-year data from the BIOFLOW-V trial, which was presented yesterday at the 2020 CRT Congress. The three-year follow-up data demonstrates consistently lower clinical event rates and improvement in patient outcomes, reinfo...
Read more
2019
18
October
2019
| 14:54 Europe/Amsterdam
  About 30 percent of patients undergoing primary percutaneous coronary intervention (PCI) suffer from ST-Elevation Myocardial Infarction (STEMI) – the most acute form of coronary artery disease. It’s caused by a complete thrombotic occlusion and ...
Read more
30
September
2019
| 00:00 Europe/Amsterdam
Full cohort data from the BIOSOLVE-IV registry strengthen the clinical evidence for BIOTRONIK’s Magmaris®1 Resorbable Magnesium Scaffold (RMS) as a therapy option for patients with coronary artery disease. Dr. Stefan Verheye, Senior Interventional Ca...
Read more
11
September
2019
| 00:00 Europe/Amsterdam
Twelve-month results of the BIOFLEX COF trial have demonstrated that the implantation of stents with low chronic outward force1 (COF) was associated with less neointimal hyperplasia2, consequently resulting in less restenosis. Patients treated with B...
Read more
22
July
2019
| 00:00 Europe/Amsterdam
BIOTRONIK today announced the publication of the SENSE Trial results in the Journal of Cardiac Electrophysiology, proving BIOTRONIK’s DX system is equivalent to dual-chamber implantable cardioverter defibrillators (ICDs) in detecting atrial high-rate...
Read more
07
June
2019
| 00:00 Europe/Amsterdam
New data from the BIOSOLVE-IV registry strengthen the clinical evidence for the Magmaris®1 resorbable scaffold device and procedure success and safety profile at one year. Dr. Stefan Verheye, Senior Interventional Cardiologist at Antwerp Cardiovascul...
Read more
27
May
2019
| 00:00 Europe/Amsterdam
BIOTRONIK announced today that the first patient for the BIO|MASTER.Cor Family study was enrolled at Pauls Stradins Clinical University Hospital in Riga, Latvia at the cardiology department led by Prof. Andrejs Erglis. The patient received a Rivacor ...
Read more
06
May
2019
| 00:00 Europe/Amsterdam
BIOTRONIK today announced initial enrollment into the BIO-LIBRA study, a first-of-its kind, large-scale prospective study to analyze sex-specific outcomes in patients with non-ischemic cardiomyopathy (NICM) treated with cardiac defibrillator device t...
Read more
06
May
2019
| 00:00 Europe/Amsterdam
The observational THORN registry1 highlights the importance of rapid corrective action by medical staff in cases of inappropriate diagnosis and therapy using implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy defibri...
Read more
06
March
2019
| 00:00 Europe/Amsterdam
Three-year outcome data from the BIO-RESORT1 randomized controlled trial were presented in a late-breaking clinical trials session by Dr. Clemens von Birgelen, Thoraxcentrum Twente, MST, Enschede, The Netherlands. Results from this large three-arm tr...
Read more
05
March
2019
| 00:00 Europe/Amsterdam
Preliminary data from the BIOSOLVE-IV registry strengthen the clinical evidence in favor of BIOTRONIK’s resorbable magnesium scaffold Magmaris®1 for de novo coronary artery lesions. Presented as late-breaking clinical data at the Cardiovascular Resea...
Read more
04
March
2019
| 00:00 Europe/Amsterdam
Two-year data from the RM-ALONE Trial1 evaluating the safety and workflow efficiency of remote cardiac monitoring with remote interrogations were recently published in the European Heart Journal. The authors analyzed the efficacy of BIOTRONIK Home Mo...
Read more
12
February
2019
| 00:00 Europe/Amsterdam
Data from the BIOLUX P-III All-Comers Registry presented at LINC 2019 highlighted the safety and efficacy of BIOTRONIK’s Passeo-18 Lux* drug-coated balloon (DCB), even in challenging patient subgroups. A number of presentations during LINC congress f...
Read more
2018
17
December
2018
| 00:00 Europe/Amsterdam
BIOTRONIK has announced first enrollment in a multicenter study that aims to demonstrate that a two-lead cardiac resynchronization therapy (CRT) system with atrial sensing is at least as effective as a conventional three-lead system. BIOTRONIK’s CRT-...
Read more
Tags
PR
CRM
CRT
20
November
2018
| 00:00 Europe/Amsterdam
Following a statistical calculation error, the outcomes of SORT-OUT IX1 have recently been corrected, resulting in a change to the trial’s primary endpoint. The revised data analysis demonstrates that compared to BIOTRONIK’s Orsiroa drug-eluting sten...
Read more
28
September
2018
| 00:00 Europe/Amsterdam
During this year’s CIRSE congress, Prof. Christoph Binkert, Kantonsspital Winterthur, Switzerland, presented 24-month outcomes of the world’s second largest Real-World DCB registry, BIOLUX P-III. Data presented included the 24-month outcomes of the S...
Read more
25
September
2018
| 00:00 Europe/Amsterdam
Investigators unveiled clinical data from the independent BIONYX1 and SORT OUT IX2 all-comers trials which respectively compared durable polymer Resolute Onyxb and polymer-free BioFreedomc to bioresorbable polymer Orsiro. In both studies, patients...
Read more
24
September
2018
| 00:00 Europe/Amsterdam
Preliminary data from BIOSOLVE-IV registry shows low target lesion failure (TLF) rates of 4.3% with Magmarisa and only one case of scaffold thrombosis (after DAPT interruption before the event).1 The data presented at the TCT congress as late-brea...
Read more
24
September
2018
| 00:00 Europe/Amsterdam
Today, BIOTRONIK announced two-year data from the BIOFLOW-V randomized trial comparing the Orsiro and Xience1 drug-eluting stents (DES). The data shows statistically improved outcomes for patients treated with Orsiro across a range of clinical endpoi...
Read more
14
June
2018
| 00:00 Europe/Amsterdam
Ever since its CE launch in June 2016, BIOTRONIK’s Magmaris has been implanted by more than 650 physicians in over 350 hospitals across 45 countries. As part of its Magnesium 2,000 program, a post-market evaluation program, more than 2,000 Magmaris c...
Read more
23
May
2018
| 00:00 Europe/Amsterdam
Data presented during the EuroPCR congress on the Magmaris Resorbable Magnesium Scaffold (RMS) provide further evidence on its continued safety and efficacy, also in a more complex population. Dr. Stefan Verheye, M.D., Ph.D., Senior Interventional...
Read more
26
April
2018
| 00:00 Europe/Amsterdam
BIOTRONIK announced the latest results of three lower limb clinical trials – BIOLUX P-III, BIOFLEX PEACE and BIOLUX 4EVER ...
Read more
Tags
PR
27
March
2018
| 00:00 Europe/Amsterdam
Dr. Yang Yue Jin, Professor of Cardiology at the Fu-Wai Hospital, National Center of Cardiovascular Disease, Beijing, China, presented the 9- and 12-month results of the BIOFLOW-VI clinical study at the China Interventional Therapeutics (CIT) 2018 co...
Read more
13
March
2018
| 00:00 Europe/Amsterdam
BIOTRONIK announced today that patient enrollment for the BIOSTEMI study has been completed. STEMI is a potentially fatal type of heart attack, caused by prolonged obstruction of blood supply in the heart. More than 730,000 cardiac artery disease (CA...
Read more
01
February
2018
| 00:00 Europe/Amsterdam
The CASTLE-AF study—described as “potentially guideline-changing”, has been published in the New England Journal of Medicine .1 The trial, conducted with BIOTRONIK’s support, shows a 38 percent reduction in the composite endpoint of all-cause mortal...
Read more
Tags
PR
31
January
2018
| 00:00 Europe/Amsterdam
During a well-attended BIOTRONIK-sponsored symposium chaired by Dr. Jos van den Berg, Professor of Interventional Radiology, Ospedale Regionale di Lugano, Switzerland, panelists demonstrated that reducing metal burden in superficial femoral artery (S...
Read more
2017
02
November
2017
| 00:00 Europe/Amsterdam
BIOTRONIK’s Orsiro1 drug-eluting stent (DES) demonstrated high long-term safety and clinical performance according to 60-month follow-up data presented during TCT 2017. Data from the BIOFLOW-II randomized controlled trial was presented in a poster...
Read more
01
November
2017
| 00:00 Europe/Amsterdam
Data presented during the TCT congress on BIOTRONIK's Magmaris1 RMS provide further evidence on its continued safety and efficacy. Pooled 12-month data from the BIOSOLVE-II and BIOSOLVE-III clinical trials highlight high procedural success and the co...
Read more